The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Diabetes medications and risk of Parkinson’s disease: a cohort study of patients with diabetes
Open accessAbstract
The elevated risk of Parkinson’s disease in patients with diabetes might be mitigated depending on the type of drugs prescribed to treat diabetes. Population data for risk of Parkinson’s disease in users of the newer types of drugs used in diabetes are scarce. We compared the risk of Parkinson’s disease in patients with diabetes exposed to thiazolidinediones (glitazones), glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase 4 (DPP4) inhibitors, with the risk of Parkinson’s disease of users of any other oral glucose lowering drugs. A population-based, longitudinal, cohort study was conducted using historic primary care data from The Health Improvement Network. Patients with a diagnosis of diabetes and a minimum of two prescriptions for diabetes medications between January 2006 and January 2019 were included in our study. The primary outcome was the first recording of a diagnosis of Parkinson’s disease after the index date, identified from clinical records. We compared the risk of Parkinson’s disease in individuals treated with glitazones or DPP4 inhibitors and/or GLP-1 receptor agonists to individuals treated with other antidiabetic agents using a Cox regression with inverse probability of treatment weighting based on propensity scores. Results were analysed separately for insulin users. Among 100 288 patients [mean age 62.8 years (standard deviation 12.6)], 329 (0.3%) were diagnosed with Parkinson’s disease during the median follow-up of 3.33 years. The incidence of Parkinson’s disease was 8 per 10 000 person-years in 21 175 patients using glitazones, 5 per 10 000 person-years in 36 897 patients using DPP4 inhibitors and 4 per 10 000 person-years in 10 684 using GLP-1 mimetics, 6861 of whom were prescribed GTZ and/or DPP4 inhibitors prior to using GLP-1 mimetics. Compared with the incidence of Parkinson’s disease in the comparison group (10 per 10 000 person-years), adjusted results showed no evidence of any association between the use of glitazones and Parkinson’s disease [incidence rate ratio (IRR) 1.17; 95% confidence interval (CI) 0.76–1.63; P = 0.467], but there was strong evidence of an inverse association between use of DPP4 inhibitors and GLP-1 mimetics and the onset of Parkinson’s disease (IRR 0.64; 95% CI 0.43–0.88; P < 0.01 and IRR 0.38; 95% CI 0.17–0.60; P < 0.01, respectively). Results for insulin users were in the same direction, but the overall size of this group was small. The incidence of Parkinson’s disease in patients diagnosed with diabetes varies substantially depending on the treatment for diabetes received. The use of DPP4 inhibitors and/or GLP-1 mimetics is associated with a lower rate of Parkinson’s disease compared to the use of other oral antidiabetic drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“diabetic patients receiving GLP-1R agonists are associated with a lower risk of developing PD.”
From Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases (2024) · cites this paper as [615]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Austin, P. C. (2011) · Multivariate Behavioral Research · doi:10.1080/00273171.2011.568786 · Cited by 12,242
Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson’s disease
Yun, S. P., Kam, T.-I., Panicker, N., Kim, S., Oh, Y., Park, J.-S., Kwon, S.-H., Park, Y. J., Karuppagounder, S. S., Park, H., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0051-5 · Cited by 1,123
Prevalence of Parkinson’s disease across North America
Marras, C., Beck, J. C., Bower, J. H., Roberts, E. M., Ritz, B. R., Ross, G. W., Abbott, R. D., Savica, R., Eeden, S. K. V. D., Willis, A. W., et al. (2018) · npj Parkinson s Disease · doi:10.1038/s41531-018-0058-0 · Cited by 982
Athauda, D., Maclagan, K., Skene, S. S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., Hibbert, S., Budnik, N., Zampedri, L., Dickson, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31585-4 · Cited by 889 · cited 3×
“The positive markers from this population study seem to be further supported by the findings of potential disease modifying effects of two single centre phase 2 interventional studies (Aviles-Olmos et al., 2014; Athauda et al., 2017).”
BackgroundResultSelf-citationBlak, B., Thompson, M., Dattani, H., & Bourke, A. (2011) · Journal of Innovation in Health Informatics · doi:10.14236/jhi.v19i4.820 · Cited by 630
Exenatide and the treatment of patients with Parkinson's disease
Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Ell, P., Soderlund, T., Whitton, P., Wyse, R., Isaacs, T., Lees, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68295 · Cited by 529
Self-citationInsulin resistance and Parkinson’s disease: A new target for disease modification?
Athauda, D. S., & Foltynie, T. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.10.001 · Cited by 340
Self-citationHow valid is the clinical diagnosis of Parkinson's disease in the community?
Schrag, A. E. (2002) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.73.5.529 · Cited by 308
Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson’s Disease
Avilés-Olmos, I., Dickson, J. C., Kefalopoulou, Z. M., Djamshidian, A., Kahan, J., Ell, P. J., Whitton, P. S., Wyse, R. K. H., Isaacs, T., Lees, A. J., et al. (2014) · Journal of Parkinson s Disease · doi:10.3233/jpd-140364 · Cited by 300
Self-citationPioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial
(2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00144-1 · Cited by 286
Leyrat, C., Seaman, S. R., White, I. R., Douglas, I., Smeeth, L. L., Kim, J., Resche‐Rigon, M., Carpenter, J. R., & Williamson, E. (2017) · Statistical Methods in Medical Research · doi:10.1177/0962280217713032 · Cited by 271
Diabetes and Risk of Parkinson’s Disease
Cereda, E., Barichella, M., Pedrolli, C., Klersy, C., Cassani, E., Caccialanza, R., & Pezzoli, G. (2011) · Diabetes Care · doi:10.2337/dc11-1584 · Cited by 247
Association between diabetes and subsequent Parkinson disease: A record-linkage cohort study
De Pablo-Fernandez, E., Goldacre, R., Pakpoor, J., Noyce, A. J., & Warner, T. T. (2018) · Neurology · doi:10.1212/wnl.0000000000005771 · Cited by 242
Potential Role of Glucagon-Like Peptide-1 (GLP-1) in Neuroprotection
Hölscher, C. (2012) · CNS Drugs · doi:10.2165/11635890-000000000-00000 · Cited by 198
Identifying periods of acceptable computer usage in primary care research databases
Horsfall, L., Walters, K., & Petersen, I. (2013) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3368 · Cited by 148
Brauer, R., Bhaskaran, K., Chaturvedi, N., Dexter, D. T., Smeeth, L. L., & Douglas, I. (2015) · PLoS Medicine · doi:10.1371/journal.pmed.1001854 · Cited by 130
Self-citationGLP-1’s role in neuroprotection: a systematic review
Erbil, D., Eren, C. Y., Demirel, Ç., Küçüker, M. U., Solaroğlu, İ., & Eser, H. Y. (2019) · Brain Injury · doi:10.1080/02699052.2019.1587000 · Cited by 129
Glitazone use associated with reduced risk of Parkinson's disease
Brakedal, B., Flønes, I. H., Reiter, S. F., Torkildsen, Ø., Dölle, C., Aßmus, J., Haugarvoll, K., & Tzoulis, C. (2017) · Movement Disorders · doi:10.1002/mds.27128 · Cited by 108
Body Mass Index, Diabetes, and the Risk of Parkinson's Disease
Jeong, S., Han, K., Kim, D., Rhee, S. Y., Jang, W., & Shin, D. W. (2019) · Movement Disorders · doi:10.1002/mds.27922 · Cited by 104
Svenningsson, P., Wirdefeldt, K., Yin, L., Fang, F., Markaki, I., Efendić, S., & Ludvigsson, J. F. (2016) · Movement Disorders · doi:10.1002/mds.26734 · Cited by 103
Tran, K., Park, Y. I., Pandya, S., Muliyil, N. J., Jensen, B. D., Huynh, K., & Nguyen, Q. P. H. (2017) · PubMed Central · Cited by 102
A Practical Guide for Using Propensity Score Weighting in R
Olmos, A., & Govindasamy, P. (2020) · ScholarWorks@UMassAmherst (University of Massachusetts Amherst) · doi:10.7275/jjtm-r398 · Cited by 91
A prospective study of alcoholism and the risk of Parkinson?s disease
Hernán, M. Á., Logroscino, G., & guez, L. A. G. A. R. (2004) · Journal of Neurology · doi:10.1007/s00415-004-1705-4 · Cited by 58
Fang, F., Zhan, Y., Zhuo, Y., Yin, D., Li, K., & Wang, Y. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12646 · Cited by 40
Thiazolidinediones and Parkinson Disease: A Cohort Study
Connolly, J. G., Bykov, K., & Gagne, J. J. (2015) · American Journal of Epidemiology · doi:10.1093/aje/kwv109 · Cited by 39
Impact of small vessel disease on severity of motor and cognitive impairment in Parkinson’s disease
Schwartz, R. S., Halliday, G. M., Soh, D., Cordato, D. J., & Kril, J. J. (2018) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2018.10.029 · Cited by 24
Flagged first, then by citations
Research works printed but not linked: 1
- British National Formulary, 77, March
Cited by
Sorted by citations
Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases
Loh, J. S., Mak, W. Q., Tan, L. K. S., Ng, C. X., Chan, H. H., Yeow, S. H., Foo, J. B., Ong, Y. S., How, C. W., & Khaw, K. Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01743-1 · Cited by 1,193
GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
Zhao, X., Wang, M., Wen, Z., Lu, Z., Cui, L., Fu, C., Xue, H., Liu, Y., & Zhang, Y. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.721135 · Cited by 463
Trial of Lixisenatide in Early Parkinson’s Disease
Meissner, W. G., Remy, P., Giordana, C., Maltête, D., Derkinderen, P., Houéto, J.-L., Anheim, M., Benatru, I., Boraud, T., Brefel-Courbon, C., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2312323 · Cited by 369
Kopp, K. O., Glotfelty, E. J., Li, Y., & Greig, N. H. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106550 · Cited by 298
Ramasubbu, K., & Rajeswari, V. D. (2022) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-022-04587-x · Cited by 256
Metadata
- Authors
- Brauer, R., Wei, L., Ma, T., Athauda, D., Girges, C., Vijiaratnam, N., Auld, G., Whittlesea, C., Wong, I., & Foltynie, T.
- Affiliations
- UCL School of Pharmacy (GB)
- National Hospital for Neurology and Neurosurgery (GB)
- Department of Clinical and Movement Neurosciences, UCL Institute of Neurology, Queen Square, London, UK
- Corresponding author
- Wei, Li
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-10-01
- Volume
- 143
- Issue
- 10
- Pages
- 3067-3076
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC7794498
- OpenAlex
- W3089728969
- Cited by
- 233
- References
- 26
- Citations by year
- 2026: 31 · 2025: 56 · 2024: 45 · 2023: 33 · 2022: 38 · 2021: 27 · 2020: 3
- FWCI
- 10.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Brain (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- The Cure Parkinson's Trust (LW011)
- Cure Parkinson’s Trust
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Keywords
- Parkinson's disease, antidiabetic drugs, thiazolidinediones, GLP-1 receptor agonists, DPP-4 inhibitors, insulin, drug safety, type 2 diabetes, type 1 diabetes, Health Improvement Network, propensity score matching, inverse probability of treatment weighting, confounding by indication
- MeSH terms
- Aged, Diabetes Mellitus, Type 2, Female, United Kingdom, Humans, Hypoglycemic Agents, Longitudinal Studies, Male, Middle Aged, Parkinson Disease, Risk Factors, Cohort Studies, Glucagon-Like Peptide 1, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
